DUBLIN--(BUSINESS WIRE)--The "Global Krabbe Disease Treatment Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
Global krabbe disease treatment market to grow at a CAGR of 7.24% during the period 2018-2022.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend in the market is emergence of pharmacological chaperone therapy. More than two-fifth known cases of Krabbe disease are due to missense mutation in the GLC enzyme. Such mutations result in the disruption of enzyme folding and ultimately stops the GLC from reaching its site of action in enough amounts in the lysosome.
According to the report, one driver in the market is special drug designation. An important factor that is expected to drive market growth is the assignment of special drug designations to drugs and biologics that are intended for the safe and effective treatment of Krabbe disease. The priority review program for facilitating fast drug approvals is offered by the Food and Drug Administration (FDA).
Further, the report states that one challenge in the market is limited patient pool for clinical trials.
- Johnson & Johnson
Key Topics Covered:
Part 01: Executive Summary
Part 02: Scope of the Report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Market Landscape
Part 06: Market Sizing
Part 07: Five Forces Analysis
Part 08: Pipeline Analysis
Part 09: Market Segmentation by Therapy
Part 10: Customer Landscape
Part 11: Regional Landscape
Part 12: Decision Framework
Part 13: Drivers and Challenges
Part 14: Market Trends
Part 15: Vendor Landscape
Part 16: Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/c95tm4/global_krabbe?w=4